What is Ablative Solutions?
Headquartered in Wakefield, Massachusetts, Ablative Solutions operates at the intersection of medical technology and cardiovascular health. The company is primarily focused on the development of the Peregrine System, a novel therapeutic platform designed to treat hypertension by modulating the sympathetic nervous system. This approach is particularly relevant for patients suffering from comorbid conditions such as heart failure, kidney disease, metabolic syndrome, and sleep apnea. By providing a procedural alternative to standard antihypertensive medication, Ablative Solutions is carving out a critical niche in the global healthcare market, emphasizing clinical efficacy and patient-centric outcomes in the management of systemic blood pressure disorders.
How much funding has Ablative Solutions raised?
Ablative Solutions has raised a total of $149.8M across 9 funding rounds:
Debt
$3M
Series A
$5.4M
Debt
$8M
Series B
$9.5M
Series C
$14.6M
Unspecified
$2.5M
Private Equity
$11.4M
Debt
$4M
Series D
$91.4M
Debt (2011): $3.1M, investors not publicly disclosed
Series A (2012): $5.4M led by Michigan Accelerator Fund and BioStar Capital
Debt (2013): $8M, investors not publicly disclosed
Series B (2014): $9.5M featuring BioStar Capital and Michigan Accelerator Fund I
Series C (2015): $14.6M, investors not publicly disclosed
Unspecified (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $11.4M, investors not publicly disclosed
Debt (2017): $4M, investors not publicly disclosed
Series D (2022): $91.4M featuring Gilde Healthcare, Invus Opportunities, and BioStar Capital
Key Investors in Ablative Solutions
BioStar Capital
BioStar Capital is a visionary healthcare investor focused on transformative medical devices, combining business acumen with clinical expertise to drive life-changing patient outcomes.
Gilde Healthcare
Gilde Healthcare is a specialized investment firm managing over 1.4 billion euros, focusing on venture and growth opportunities that enable better care at lower costs.
Michigan Accelerator Fund
Michigan Accelerator Fund provides strategic backing to high-growth companies, leveraging a network of resources to foster innovation and commercial success.
What's next for Ablative Solutions?
With the recent influx of capital, Ablative Solutions is well-positioned to accelerate its clinical development pipeline and expand the reach of its Peregrine System. The company's strategic roadmap likely involves scaling its regulatory efforts and deepening its market penetration within the cardiovascular sector. As the firm transitions from late-stage development to broader commercialization, the focus will remain on validating the long-term clinical benefits of its sympathetic denervation technology. Investors and industry stakeholders are closely monitoring the company's progress as it seeks to redefine the standard of care for hypertension, potentially disrupting the multi-billion dollar market for cardiovascular therapeutics through its unique, device-based intervention strategy.
See full Ablative Solutions company page
